Zhen‐Ping Zou
Papers
1
Total Citations
142
H-Index
1
About
Zhen-Ping Zou is a pioneering researcher at the intersection of synthetic biology and gastrointestinal disease, whose work has redefined the potential of engineered probiotics as living diagnostics and therapeutics. His landmark 2022 study, cited 142 times, introduced a groundbreaking biomarker-responsive probiotic that not only diagnoses inflammatory bowel disease (IBD) in mice but also records disease activity and actively ameliorates inflammation. This triple-function platform—sensing, memory, and treatment—represents a paradigm shift in precision medicine, offering a non-invasive, self-regulating approach to managing chronic gut disorders. By integrating synthetic gene circuits into commensal bacteria, Zou has demonstrated how living therapeutics can provide real-time disease monitoring and on-demand drug delivery, addressing critical gaps in IBD management. His work has profound implications for translating engineered microbes into clinical tools, inspiring a new generation of researchers to explore microbial-based solutions for complex inflammatory conditions. With this highly cited study as a cornerstone, Zou continues to advance the field, merging molecular engineering with microbiome science to create intelligent, responsive therapies that could transform patient care.
Research Focus
Key Achievements
Top Papers
- 1